Share

IN THIS ISSUE

The arrival of Covid-19 has put pharma companies under increased pressure to deliver positive results, but this is not the first time that the industry has been forced to rapidly respond to global health threats. One such threat is the mumps, a viral disease that is once again on the rise in England despite the existence of the MMR vaccine. To find out what is behind this ten-year peak in cases, we track the history of the condition and the treatments developed to prevent it. Plus, we investigate the role that whistleblowers play in global pandemics, and find out what happened to the individuals who went above and beyond to warn people about the spread of diseases.


Moving away from viruses, we take a look at a cancer treatment that shuns the personalised medicine trend by targeting the oncoprotein Myc, which is found in most cancers, talk to supply chain management company Origin about pharma’s role in dealing with the health effects of climate change, and find out what manufacturers do to maximise the tolerability and safety of medications and their inactive ingredients.


Plus, we ask if 2020 will be the year of the pharma spin out company, speak to Genocea CEO and president Chip Clark about improving cancer treatments, and get a step by step guide through Signals Analytics’ pharma playbook to find out how the system can support drug development and partnerships.

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue